A preexisting CD8+ T-cell response may be predictive of benefit from checkpoint blockade in SCLC.
For patients with locally advanced non-small cell lung cancer (NSCLC), deep-learning networks integrating computed tomography (CT) scans at multiple time points can improve clinical outcome predictions.
Sustained use of inhaled corticosteroids is associated with a reduced risk for lung cancer in patients with COPD.
Higher cardiorespiratory fitness (CRF) is associated with a lower risk for incident lung and colorectal cancer and with a lower risk for all-cause mortality among those diagnosed with lung and colorectal cancer.
Treatment with pembrolizumab may be more effective than chemotherapy for improving overall survival in patients with locally advanced or metastatic non-small-cell lung cancer.
Crude estimated rates of physician-patient discussion dropped from 6.7 to 4.3 percent in 2012 to 2017
Linking EHRs with genomic profiling data from patients with NSCLC supported associations seen in clinical trials.
Future studies will look at combining the therapy with anti-PD1 blockade.
Merck announced that the Food and Drug Administration (FDA) has approved Keytruda (pembrolizumab) as monotherapy for the first-line treatment of patients with stage III non-small cell lung cancer (NSCLC) who are not candidates for surgical resection or definitive chemoradiation, or metastatic NSCLC, and whose tumors express PD-L1 (tumor proportion score [TPS] ≥1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations.
A number of different definitions of immunotherapy-related hyperprogression are currently in use.
Exposure of patients with small cell lung cancer to platinum-based chemotherapy resulted in altered levels of specific plasma lipids.
Perioperative administration of landiolol was associated with trends toward improved relapse-free and overall survival in patients undergoing lung cancer resection.
In this study, no patients receiving sequential administration of an immune checkpoint inhibitor followed by erlotinib developed a severe immune-related AE.
Prophylactic brain irradiation was associated with a significant improvement in disease-free survival and a significant reduction in likelihood of developing brain metastases.
The Food and Drug Administration (FDA) has approved Tecentriq (atezolizumab; Genentech), in combination with carboplatin and etoposide, for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).
Whole-genome sequencing of tumor specimens from patients with chemoresistant SCLC showed evidence of the deletion of multiple tumor suppressor genes.
Reductions in the risk of cancer were more pronounced in men and younger patients with vitiligo.
NSCLC characterized by ALK or EGFR molecular alterations produced different findings on CT scan images.
The Guardant360 assay is as effective as traditional tumor-based genotyping assays in identifying genomic alterations, according to researchers.
This study was presented at the 2019 International Congress on Targeted Anticancer Therapies (TAT) in Paris, France, from February 25-27, 2019. Dr Jun Sato of the National Cancer Center Hospital, Japan is the lead author of this study.1 Results from a retrospective study evaluating the focus of early-phase clinical trials of investigational drug candidates in…